Enovis Corporation (ENOV) — ESG & Values Scores

Environment story

Enovis discloses minimal quantitative environmental data in its 10-K filing. Scope 1, 2, and 3 emissions figures are undisclosed, and no net-zero target year is stated. The company acknowledges climate-related supply-chain risks (raw material sourcing disruptions, tariffs affecting manufacturing) but provides no evidence of decarbonization initiatives, renewable energy commitments, or carbon reduction targets. Manufacturing facility disruptions due to climate events are mentioned as a risk but without corresponding mitigation strategies. The absence of disclosed emissions, targets, and sustainability commitments results in substantial deductions. No greenwashing flags detected, as the company makes no public climate claims to audit.

Criticisms on file

Climate-related operational risk: Risk factors explicitly identify exposure to climate change impacts on manufacturing facilities (natural disasters, adverse weather, power outages) without disclosed mitigation or resilience planning.
Source: ENOV 10-K, Item 1A Risk Factors, 'A material disruption at any of our manufacturing facilities'

Disclosed initiatives

No disclosed initiatives on file for this pillar.

Social story

Enovis provides no disclosed diversity metrics, CEO-to-worker pay ratios, or turnover data in the 10-K filing. The company acknowledges dependence on a direct sales force in the United States and Europe for orthopedic rehabilitation products but does not disclose labor relations status, union standing, or any notable labor disputes. No supply-chain labor audits, human rights assessments, or diversity programs are described. The absence of quantitative social metrics and no evidence of active labor controversies results in a moderate score reflecting limited transparency rather than active violations. The company does not disclose whether it has experienced NLRB complaints, strikes, or union-suppression activities.

Criticisms on file

Supply-chain raw material sourcing: 10-K notes dependency on suppliers in China and Asia; political/economic instability and health emergencies could disrupt supply, with no disclosed supply-chain labor audit or human rights due diligence mentioned.
Source: ENOV 10-K, Item 1A Risk Factors, 'We are dependent on the availability of raw materials'

Disclosed initiatives

Direct Sales Force Employment

Company maintains direct sales force in United States and Europe for orthopedic rehabilitation products, which is acknowledged as a fixed-cost model.

Governance story

Enovis 10-K does not disclose board independence percentage, board composition, or share structure details. The filing mentions that the company's Amended and Restated Certificate of Incorporation contains provisions that may delay third-party acquisitions without board consent, and Delaware law provides anti-takeover protections, but does not clarify dual-class share structures. Lobbying expenditures are not disclosed. The company has incurred significant goodwill impairment charges ($501.0M in Q4 2025, $540.8M in Q3 2025, $645.0M in 2024), suggesting prior valuation assessment weaknesses. No active antitrust or major regulatory consent decrees are mentioned, but the company acknowledges exposure to FDA enforcement risk, healthcare fraud and abuse law investigations, HIPAA compliance risk, and data privacy enforcement. The absence of disclosed governance metrics, combined with large intangible asset write-downs, results in a moderate score.

Criticisms on file

Regulatory investigation exposure: Company acknowledges it has received and may continue to receive subpoenas from U.S. Department of Justice and HHS Office of Inspector General relating to financial arrangements with healthcare providers and promotional practices, which present compliance risk under healthcare fraud and abuse laws.
Source: ENOV 10-K, Item 1A Risk Factors, 'Our relationships with customers, physicians and third-party payors are subject to federal and state health care fraud and abuse laws'
Data security incident (2025): A third-party cloud service provider experienced a cybersecurity incident that impacted Enovis and compromised certain business and personal information records; company required to investigate, remediate, and issue notifications.
Source: ENOV 10-K, Item 1A Risk Factors, 'Our information technology infrastructure and information are vulnerable to service interruptions'
Goodwill impairment charges totaling $1.69 billion across 2024–2025, reflecting sustained decrease in publicly quoted share price and market capitalization relative to carrying value of reporting units; suggests prior acquisition valuations were overstated.
Source: ENOV 10-K, Item 1A Risk Factors, 'Any further impairment in the value of our intangible assets, including Goodwill, would negatively affect our operating results'

Disclosed initiatives

Internal Control Compliance (Sarbanes-Oxley Act)

Company assesses effectiveness of internal control over financial reporting for acquired companies and implements or enhances controls at acquisitions to comply with SOX requirements.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Enovis Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Enovis Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)